Table 3.
Epidemiological, clinical and pathological patterns of patients diagnosed with cervical cancer (n = 24).
| Pre-Pandemic (2019) | Pandemic with High Restrictions (2020) |
Pandemic Recovery (2021) | p | |
|---|---|---|---|---|
| Number of patients, n | 8 | 6 | 10 | |
| Age at diagnosis, median (IQR; Min-Max), years | 63.5 (27; 35–77) | 69.0 (23; 55–84) | 47.5 (32; 39–80) | 0.251 |
| Postmenopausal status, n (%) | 6 (75.0) | 6 (100.0) | 4 (40.0) | 0.040 * |
|
Histological type, n (%) Squamous cell carcinoma Adenocarcinoma Carcinosarcoma/sarcoma |
6 (75.0) 1 (12.5) 1 (12.5) |
4 (66.7) 2 (33.3) 0 (0.0) |
7 (70.0) 2 (20.0) 1 (10.0) |
0.835 |
|
Tumor staging1, n (%) Initial stage (IA1-IB2, IIA1) Advanced stage (IB3, IIA2, IIB-IV) |
1 (12.5) 7 (87.5) |
1 (16.7) 5 (83.3) |
3 (30.0) 7 (70.0) |
0.635 |
| Time between first MDTM and treatment initiation, median (IQR; Min-Max), days | 52.0 (43; 35–90) | 60.0 (-; 20–123) | 41.0 (26; 20–71) | 0.445 |
|
Therapeutic management, n (%) Chemoradiotherapy Surgery Palliative No treatment 2 |
0 (0.0) 3 (37.5) 2 (25.0) 3 (37.5) |
2 (33.3) 1 (16.7) 0 (0.0) 3 (50.0) |
1 (40.0) 3 (30.0) 2 (20.0) 1 (10.0) |
0.292 |
| Hospitalization days, median (Min-Max) | 5.0 (5–8) | - | 7.0 (6–8) | 0.660 |
| Intra- and post-operative complications, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
| Time between surgery and histological assessment, median (Min-Max), days | 17.0 (13–32) | - | 27.0 (21–48) | 0.319 |
| Adjuvant therapy, n (%) | 1 (12.5) | 0 (0.0) | 1 (10.0) | 0.683 |
Legend: IQR—interquartile range; MDTM—multidisciplinary team meeting. 1 Tumor staging was assessed using the International Federation of Gynecology and Obstetrics (FIGO) Classification 2018 [21]. 2 Patients under surveillance, lost to follow-up or death. * Statistically significant differences for a significance level of 0.05.